NeurAxis to Participate in Major Investor Conference
NeurAxis, Inc. (NYSE American: NRXS), a leading medical technology innovator specializing in neuromodulation therapies, is set to participate in the upcoming Lytham Partners Spring 2025 Investor Conference. This engaging event will take place virtually, providing an important platform for the company to connect with investors and showcase its groundbreaking work.
Webcast Presentation Details
NeurAxis will kick off its participation with a webcast presentation scheduled for 9:30 a.m. ET on May 29, 2025. During this session, company executives will delve into the innovative technologies and therapeutic solutions that are transforming the landscape of healthcare for chronic conditions affecting both children and adults. Investors interested in accessing the webcast can easily find it on the conference home page.
Replay Access
For those who cannot attend the live session, there will be a replay available after the event. This ensures that all stakeholders have the opportunity to stay informed about NeurAxis's key developments and their implications for the future of healthcare technology.
One-on-One Meetings
In addition to the formal presentation, NeurAxis management will engage in virtual one-on-one meetings throughout the conference. This personalized approach allows for deeper discussions regarding the company’s direction, innovations, and growth strategy. Interested participants are encouraged to reach out to Lytham Partners to arrange these meetings, making it a valuable opportunity for investors to pose queries and gain insight directly from the leadership team.
Building Relationships with Investors
These one-on-one meetings not only enhance investor relations but also reinforce NeurAxis’s commitment to transparency and collaboration with stakeholders who are eager to learn about the company’s progress and plans.
About NeurAxis, Inc.
Founded with a mission to revolutionize the treatment of chronic ailments, NeurAxis, Inc. utilizes cutting-edge neuromodulation technologies. A highlight of their innovations is the IB-Stim™ therapy, which is designed to address functional abdominal pain related to irritable bowel syndrome (IBS) in adolescents aged 8 to 21. The potential of IB-Stim™ showcases the company’s dedication to providing relief through evidence-based medical practices.
Clinical Trials and Future Developments
The company is currently conducting various clinical trials aimed at expanding the use of their innovative therapies to cover a range of pediatric and adult conditions that currently have significant unmet healthcare needs. This ongoing research underlines NeurAxis’s commitment to enhancing treatment options and outcomes for patients.
Contact Information for Inquiries
For any inquiries related to NeurAxis and the conference, interested parties can reach the company directly. Questions about the webcast or meetings can be directed to NeurAxis via email at info@neuraxis.com.
Engagement with Investor Relations
Additionally, further inquiries can be channeled through Ben Shamsian at Lytham Partners, providing another avenue for communication and information exchange as the event approaches.
Frequently Asked Questions
What is NeurAxis known for?
NeurAxis is a medical technology company specializing in neuromodulation therapies aimed at treating chronic and debilitating conditions.
When will NeurAxis present at the investor conference?
The webcast presentation is scheduled for 9:30 a.m. ET on May 29, 2025.
How can I access the webcast presentation?
The webcast can be accessed through the conference home page or directly via the provided links.
What is IB-Stim™ therapy?
IB-Stim™ is NeurAxis’s proprietary therapy designed to alleviate functional abdominal pain associated with IBS in young patients.
Who can I contact for more information about NeurAxis?
For information, contact NeurAxis at info@neuraxis.com or reach out to Ben Shamsian at Lytham Partners.
